What is Gyre Therapeutics, Inc.'s R&D?

Gyre Therapeutics, Inc. (GYRE) reported R&D of $6.74M in Q1 2026.

How has Gyre Therapeutics, Inc.'s R&D changed year-over-year?

Gyre Therapeutics, Inc.'s R&D increased by 117.7% year-over-year, from $3.1M to $6.74M.

What is the long-term trend for Gyre Therapeutics, Inc.'s R&D?

Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s R&D has grown at a -33.2% compound annual growth rate (CAGR), from $68.89M to $13.7M.

Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.

Gyre Therapeutics, Inc. GYRE R&D

R&D at other companies

Eli LillyLLY

$3.51B+28.4%

Madrigal Pharmaceuticals, Inc.MDGL

$108.69M+146%

Viking TherapeuticsVKTX

$150.15M+263%

Theravance BiopharmaTBPH

$5.83M-49.1%

Rigel PharmaceuticalsRIGL

$11.68M+38.4%

Zevra Therapeutics, Inc.ZVRA

$4.39M+34.8%

Segments

By segment

See full

Gyre Pharmaceuticals$5.47M+80.5%

Gyre$1.27M+1,827%

All Other Segments$0—

Other financials

Income statement

See full

Revenue$22.5M+2.1%

Gross profit$21.3M+0.6%

Operating income-$9.4M-512%

Net income-$8.7M-422%

EPS (diluted)-$0.10—

Balance sheet

See full

Cash & equivalents$37.5M+149%

Total debt$823.0K-48.1%

Total equity$101.3M+48.7%

Total assets$162.0M+24.8%

Cash flow

See full

Operating cash flow$3.2M+2,565%

CapEx$178.0K+45.9%

Free cash flow$3.0M+1,296%

Valuation

See full

Market cap$694.58M-4.7%

Enterprise value$657.9M-8.0%

P/S5.9×-1.3×

Profitability

See full

Gross margin95.1%-1.1pp

Operating margin-0.1%-10.4pp

Net margin6.3%+3.3pp

FCF margin2.6%—

Returns & leverage

See full

Return on equity8.2%+4.2pp

Debt / equity0×0.0×

Current ratio4.6×+1.0×

Where this comes from

Reported directly by Gyre Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The official record: Gyre Therapeutics, Inc.’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Gyre Therapeutics, Inc.'s r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Gyre Therapeutics, Inc.'s R&D?: Gyre Therapeutics, Inc. (GYRE) reported R&D of $6.74M in Q1 2026.
How has Gyre Therapeutics, Inc.'s R&D changed year-over-year?: Gyre Therapeutics, Inc.'s R&D increased by 117.7% year-over-year, from $3.1M to $6.74M.
What is the long-term trend for Gyre Therapeutics, Inc.'s R&D?: Over 4 years (2021 to 2025), Gyre Therapeutics, Inc.'s R&D has grown at a -33.2% compound annual growth rate (CAGR), from $68.89M to $13.7M.
What does R&D mean?: Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.